C4 Therapeutics (NASDAQ:CCCC) Given New $14.00 Price Target at Stifel Nicolaus

C4 Therapeutics (NASDAQ:CCCC) had its price objective increased by investment analysts at Stifel Nicolaus from $13.00 to $14.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 111.16% from the stock’s previous close.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. raised shares of C4 Therapeutics from an “underweight” rating to a “neutral” rating and set a $6.00 price target for the company in a research report on Monday, January 29th. Morgan Stanley increased their price target on shares of C4 Therapeutics to $8.00 and gave the stock an “equal weight” rating in a research report on Monday, February 26th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.38.

C4 Therapeutics Trading Up 2.8 %

NASDAQ:CCCC traded up $0.18 during mid-day trading on Thursday, hitting $6.63. The company’s stock had a trading volume of 168,464 shares, compared to its average volume of 3,323,912. C4 Therapeutics has a fifty-two week low of $1.06 and a fifty-two week high of $11.88. The company has a market capitalization of $456.21 million, a price-to-earnings ratio of -2.48 and a beta of 3.22. The stock has a fifty day moving average of $8.12 and a 200-day moving average of $5.74.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.01). C4 Therapeutics had a negative return on equity of 55.30% and a negative net margin of 638.34%. The business had revenue of $3.26 million during the quarter, compared to analyst estimates of $5.23 million. On average, equities analysts anticipate that C4 Therapeutics will post -1.86 earnings per share for the current fiscal year.

Institutional Trading of C4 Therapeutics

Several hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC increased its holdings in shares of C4 Therapeutics by 33.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 16,322 shares of the company’s stock worth $92,000 after buying an additional 4,063 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of C4 Therapeutics during the fourth quarter worth approximately $39,000. Raymond James & Associates grew its stake in shares of C4 Therapeutics by 8.5% during the third quarter. Raymond James & Associates now owns 91,380 shares of the company’s stock valued at $170,000 after purchasing an additional 7,146 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of C4 Therapeutics during the fourth quarter valued at approximately $49,000. Finally, Barclays PLC grew its stake in shares of C4 Therapeutics by 30.7% during the third quarter. Barclays PLC now owns 43,614 shares of the company’s stock valued at $81,000 after purchasing an additional 10,246 shares during the last quarter. Institutional investors and hedge funds own 78.81% of the company’s stock.

About C4 Therapeutics

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.